Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor

Article Abstract:

A study conjugated Trypanosoma brucei rhodesiense Tr-apoL-I with a single-domain antibody (nanobody) that efficiently targets conserved cryptic epitopes of the variant surgace glycoprotein (VSG) of trypanosomes(super 3) to generate a new manmade type of immunotoxin with potential for trypanosomiasis therapy. Treatment with the engineered conjugate resulted in clear curative and alleviating effects on acute and chronic infections of mice with both normal human serum (NHS)-resistant and NHS-sensitive trypanosomes.

United States, Care and treatment, Trypanosoma brucei, African trypanosomiasis

---

Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I

Article Abstract:

Humans have innate immunity against Trypanosoma brucei brucei that is known to involve apolipoprotein L-I (APOL1), but a case of T. evansi infection in a human was identified in India. The serum of the infected patient was found to have no trypanolytic activity, a finding linked to the lack of APOL1, and activity was restored by the addition of recombinant APOL1.

India, Health aspects, Risk factors, Development and progression, Trypanosoma, Disease/Disorder overview

---

Worms tame mast cells

Article Abstract:

The article explains the functions of the protein produced by parasitic roundworms, which apart from slowing down the inflammatory response, also prevents the activation of mast cells in humans.

Physiological aspects, Immunoglobulins, Nematoda, Nematodes, Mast cells, Chemical properties, Phosphotransferases

Similar abstracts:

• Abstracts: Importance of early diagnosis in managing ovarian cancer. Strategies for treating and managing testicular cancer
• Abstracts: Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. Heterosexually transmitted HIV infection among African Americans in North Carolina
• Abstracts: Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. Altered bone and mineral metabolism in patients receiving imatinib mesylat
• Abstracts: Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.